1
|
Ciseł B, Mielko J, Kurylcio A, Lewicka M, Sokoluk M, Jazienicki M, Skórzewska M, Sitarz R, Pikuła A, Cisło M, Romanek J, Polkowski W. 618. Compliance with perioperative systemic therapy in patients with advanced gastric cancer. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
3
|
Lewicka M, Ciseł B, Skórzewska M, Pikuła A, Cisło M, Mielko J, Sitarz R, Jazienicki M, Sokoluk M, Zuchora B, Kurylcio A, Rawicz-Pruszyński K, Polkowski W. 706. Haematological toxicity associated with hyperthermic intraperitoneal chemotherapy: Comparison of mitomycin C and oxaliplatin. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
4
|
Mielko J, Kurylcio A, Ciseł B, Sitarz R, Jazienicki M, Sokoluk M, Lewicka M, Skórzewska M, Pikuła A, Cisło M, Zuchora B, Rawicz-Pruszyński K, Polkowski W. 459. Treatment of colorectal cancer patients with synchronous liver metastases: Lublin experience. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
11
|
Mielko J, Skórzewska M, Cisel B, Romanek J, Lewicka M, Sitarz R, Budny W, Kurylcio A, Polkowski W. 431. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal surface malignancies: Analysis of the causes of disqualification. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
12
|
Thill M, Kurylcio A, Welter R, Baumann K, van Haasteren V, Grosse B, Berclaz G, Polkowski W, Hauser N. Die zentraleuropäischen SentiMag Studien: Sentinel Node Biopsie mit superparamagnetischem Eisenoxid (SPIO) vs. Radioisotop-Markierung. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
13
|
Thill M, Kurylcio A, Blechmann R, van Haasteren V, Grosse B, Berclaz G, Polkowski W, Hauser N. Abstract P1-01-02: The SentiMag study: Sentinel node biopsy with superparamagnetic iron oxide vs. radioisotope. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
The SentiMag study compares the “gold standard” 99mTc with a new technique, which employs superparamagnetic iron oxide particles (SPIO) for localization of sentinel lymph nodes. Aim of this study is to investigate the potential equivalency of the SentiMag® technique in comparison to the gold standard of sentinel lymph node biopsy (SLNB).
Materials and methods:
In a prospective, multicentre and multinational 2-arm study, 150 patients with histologically verified breast carcinoma are examined. For comparison, SLNs are marked initially with radioisotope following a 1- or 2-day protocol. Additionally, SPIO (Sienna+®) is injected in the operation room by the surgeon at least 20 minutes before SLNB into the subareolar interstitial tissue, followed by 5 minutes massage. SLN-detection is carried out using a magnetometer (SentiMag®) and a gamma probe. Preparation and excision of lymph nodes is conducted using both techniques in a parallel manner. All lymph nodes marked with either tracer are excised.
Results:
Interim analysis of 138 patients resulted in a detection rate concordance per patient of 97% (134/138). An average of 1.9 (radioisotope) and 2.0 (SPIO) lymph nodes were collected per patient. Nodal detection rate was 92% (250/273) for the radioisotope vs. 97% (265/273) for the SPIO tracer with magnetometer detection. The proportion of pathologically positive lymph nodes was 38/250 (15%) vs. 39/265 (15%) for the radioisotope and the SPIO tracer respectively. All pathologically positive lymph nodes detected with the conventional technique (radioisotope) were also detected with the new technique (SentiMag®).
Conclusions:
The SentiMag® provides an easy technique which can be rapidly implemented into daily routine. Due to the simple handling, preoperative efforts can be reduced to a minimum. If further and consistent results prove its efficacy, this technique may ultimately replace the standard of care.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-01-02.
Collapse
Affiliation(s)
- M Thill
- Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland
| | - A Kurylcio
- Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland
| | - R Blechmann
- Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland
| | - V van Haasteren
- Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland
| | - B Grosse
- Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland
| | - G Berclaz
- Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland
| | - W Polkowski
- Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland
| | - N Hauser
- Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany; Medical University of Lublin, Lublin, Poland; Interdisciplinary Breast Cancer Centre, Kantonsspital Baden, Baden, Switzerland; Breast Centre Bern, Engeriedspital, Lindenhofgruppe, Bern, Switzerland
| |
Collapse
|